Trial Profile

A Phase Ia Dose-escalation Study to Access the Tolerability Safety Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 07 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thrombopoietin (Primary)
Indications Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
Focus Adverse reactions; Pharmacokinetics
Sponsors Shenyang Sunshine Pharmaceutical

20 Mar 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
20 Mar 2020 Planned primary completion date changed from 31 Jul 2019 to 8 Oct 2020.
25 Sep 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com